Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The University of New Orleans holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there is 1 pending office action associated with this portfolio. This action reflects the university's efforts to commercialize its biotechnological research through the patent system. The prosecution activity is focused on this outstanding matter.
The portfolio's prosecution is confined to 1 distinct examiner and 1 distinct art unit. This suggests that the university's current filings are being evaluated within the assigned specialized group at the patent office. For the legal team, this means that the prosecution strategy must be aligned with the requirements of this 1 distinct art unit.
MCANANY, JOHN D is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. Since the total number of pending actions is 1, this examiner is the individual responsible for reviewing the university's active applications. Practitioners should focus on addressing the technical feedback provided by MCANANY, JOHN D.
The presence of 1 distinct art unit in the Biotechnology & Pharmaceuticals area ensures a consistent technical evaluation. With 1 pending office action, the university can dedicate its resources to achieving an outcome in this specific case. This environment simplifies the management of the university's intellectual property assets.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCANANY, JOHN D | 1 | 63.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421980 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | MCANANY, JOHN D | 73d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421980 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | MCANANY, JOHN D | 73d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17421980 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | MCANANY, JOHN D | 1625 | §102§103§112 | Non-Final OA | 73d overdue | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of New Orleans has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
John D Mcanany has the most, with 1 of University of New Orleans's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.